NASDAQ:IMAB

I-Mab News Headlines

$71.82
-1.51 (-2.06 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$71.03
$73.57
50-Day Range
$47.86
$81.07
52-Week Range
$23.61
$84.01
Volume337,970 shs
Average Volume468,373 shs
Market Capitalization$5.20 billion
P/E Ratio67.75
Dividend YieldN/A
Beta0.75

I-Mab (NASDAQ IMAB) News Headlines Today

SourceHeadline
I-Mab (NASDAQ:IMAB) Rating Lowered to Sell at Zacks Investment ResearchI-Mab (NASDAQ:IMAB) Rating Lowered to Sell at Zacks Investment Research
marketbeat.com - June 10 at 10:11 PM
I-Mab (NASDAQ:IMAB) Stock Price Down 2.8%I-Mab (NASDAQ:IMAB) Stock Price Down 2.8%
americanbankingnews.com - June 11 at 11:16 AM
I-Mab (NASDAQ:IMAB) Given New $90.00 Price Target at Cantor FitzgeraldI-Mab (NASDAQ:IMAB) Given New $90.00 Price Target at Cantor Fitzgerald
americanbankingnews.com - June 10 at 9:04 AM
Calculating The Fair Value Of I-Mab (NASDAQ:IMAB)Calculating The Fair Value Of I-Mab (NASDAQ:IMAB)
finance.yahoo.com - June 8 at 1:40 PM
I-Mab (NASDAQ:IMAB) Sees Strong Trading VolumeI-Mab (NASDAQ:IMAB) Sees Strong Trading Volume
americanbankingnews.com - June 4 at 12:21 PM
I-Mab (NASDAQ:IMAB)  Shares Down 5.4% I-Mab (NASDAQ:IMAB) Shares Down 5.4%
americanbankingnews.com - June 2 at 12:36 PM
I-Mab (NASDAQ:IMAB) Earns Buy Rating from Analysts at Daiwa Capital MarketsI-Mab (NASDAQ:IMAB) Earns Buy Rating from Analysts at Daiwa Capital Markets
americanbankingnews.com - June 2 at 8:54 AM
I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody UliledlimabI-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab
finance.yahoo.com - June 2 at 8:13 AM
I-Mab Appoints Ruyi He and Rong Shao to Board of DirectorsI-Mab Appoints Ruyi He and Rong Shao to Board of Directors
finance.yahoo.com - June 1 at 12:49 PM
I-Mab (NASDAQ:IMAB) Trading 8.9% Higher I-Mab (NASDAQ:IMAB) Trading 8.9% Higher
americanbankingnews.com - May 27 at 11:57 AM
I-Mab (NASDAQ:IMAB) Sets New 52-Week High at $73.48I-Mab (NASDAQ:IMAB) Sets New 52-Week High at $73.48
americanbankingnews.com - May 26 at 1:19 PM
First Week of January 2022 Options Trading For I-Mab (IMAB)First Week of January 2022 Options Trading For I-Mab (IMAB)
nasdaq.com - May 21 at 3:19 PM
I-Mab (NASDAQ:IMAB) Shares Gap Up to $63.46I-Mab (NASDAQ:IMAB) Shares Gap Up to $63.46
americanbankingnews.com - May 21 at 10:43 AM
Why I-MABs Stock Is Trading Higher TodayWhy I-MAB's Stock Is Trading Higher Today
msn.com - May 20 at 7:01 PM
I-Mab (NASDAQ:IMAB) Shares Up 10.3%I-Mab (NASDAQ:IMAB) Shares Up 10.3%
americanbankingnews.com - May 20 at 11:38 AM
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021
finance.yahoo.com - May 19 at 6:48 PM
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic SyndromeI-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
finance.yahoo.com - May 18 at 12:12 PM
I-Mab Added to MSCI China IndexI-Mab Added to MSCI China Index
finance.yahoo.com - May 13 at 8:40 AM
I-Mab Filed 2020 Annual Report on Form 20-FI-Mab Filed 2020 Annual Report on Form 20-F
finance.yahoo.com - April 28 at 9:33 AM
I-Mabs IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis StudyI-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
finance.yahoo.com - April 26 at 2:00 PM
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative ColitisI-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
finance.yahoo.com - April 26 at 9:00 AM
Read This Before Judging I-Mabs (NASDAQ:IMAB) ROERead This Before Judging I-Mab's (NASDAQ:IMAB) ROE
nasdaq.com - April 22 at 7:45 AM
First Week of June 18th Options Trading For I-Mab (IMAB)First Week of June 18th Options Trading For I-Mab (IMAB)
nasdaq.com - April 21 at 8:23 PM
I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual MeetingI-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
finance.yahoo.com - April 14 at 9:56 AM
Shanghai Genchem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific AntibodiesShanghai Genchem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific Antibodies
finance.yahoo.com - April 6 at 1:01 PM
I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid TumorsI-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
finance.yahoo.com - April 6 at 1:01 PM
I-Mab collaborates with Chinas Genechem to develop bi-specific antibodiesI-Mab collaborates with China's Genechem to develop bi-specific antibodies
seekingalpha.com - April 6 at 10:57 AM
Should I-Mab (NASDAQ:IMAB) Focus On Improving This Fundamental Metric?Should I-Mab (NASDAQ:IMAB) Focus On Improving This Fundamental Metric?
finance.yahoo.com - March 31 at 1:49 PM
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid TumorsI-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
finance.yahoo.com - March 30 at 12:44 PM
I-Mab Reports Financial Results for Full Year of 2020 and Provides Business UpdatesI-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates
finance.yahoo.com - March 29 at 10:29 AM
I-Mab to Host 2021 R&D DayI-Mab to Host 2021 R&D Day
finance.yahoo.com - March 24 at 9:33 AM
I-Mab Files Prospectus Supplement for Shelf Registration for HillhouseI-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
finance.yahoo.com - March 19 at 6:49 PM
I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish InitiationI-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation
markets.businessinsider.com - March 15 at 12:05 PM
I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual MeetingI-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 11 at 12:10 PM
I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology PipelineI-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
markets.businessinsider.com - March 10 at 1:34 PM
I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology PipelineI-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
finance.yahoo.com - March 10 at 1:34 PM
Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology TargetsComplix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets
feeds.benzinga.com - March 10 at 8:28 AM
I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021
finance.yahoo.com - March 3 at 9:26 AM
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has PricedRegistered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
finance.yahoo.com - February 9 at 9:49 AM
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-MabProposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
finance.yahoo.com - February 5 at 7:33 PM
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
finance.yahoo.com - February 5 at 9:24 AM
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in ChinaI-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
finance.yahoo.com - February 4 at 12:19 PM
MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced CancerMorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
finanznachrichten.de - January 25 at 7:44 PM
I-Mab Announces Upcoming Participation at January ConferencesI-Mab Announces Upcoming Participation at January Conferences
finance.yahoo.com - December 23 at 1:17 PM
I-Mabs (NASDAQ:IMAB) Intrinsic Value Is Potentially 23% Below Its Share PriceI-Mab's (NASDAQ:IMAB) Intrinsic Value Is Potentially 23% Below Its Share Price
finance.yahoo.com - December 21 at 12:26 PM
I-Mab Added to Nasdaq Biotechnology IndexI-Mab Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 14 at 9:00 AM
Is IMAB A Good Stock To Buy Now?Is IMAB A Good Stock To Buy Now?
finance.yahoo.com - December 11 at 3:15 PM
Week In Review: CANbridge Closes $43 Million E Round For Rare Disease DrugsWeek In Review: CANbridge Closes $43 Million E Round For Rare Disease Drugs
seekingalpha.com - December 6 at 4:12 PM
I-Mab Files Shelf Registration Statement for PIPE InvestorsI-Mab Files Shelf Registration Statement for PIPE Investors
finance.yahoo.com - December 1 at 4:37 PM
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory BoardI-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board
finance.yahoo.com - December 1 at 8:31 AM
I-Mabs C5aR antibody TJ210/MOR210 shows strong scientific rationale as potential treatment for cancersI-Mab's C5aR antibody TJ210/MOR210 shows strong scientific rationale as potential treatment for cancers
seekingalpha.com - November 11 at 9:16 AM
This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.